摘要
目的:定性分析雄激素受体(AR)、雌激素受体(ER)、孕激素受体(PR)在良性前列腺增生(BPH)和前列腺癌(PCa)组织中的阳性表达,为激素治疗PCa和预后判断提供一定的依据。方法:采用免疫组化DAKO Envision二步法,分析30例BPH与32例PCa标本中AR、ER、PR的阳性表达情况。结果:AR、ER、PR阳性数BPH组分别为22、10、6例;PCa组分别为18、14、2例,两组差异无显著性。随访30例PCa患者术后的生存期表明:AR表达阳性者平均生存时间为6.41年,AR阴性者为4.28年,两者差异有统计学意义(P<0.05)。结论:BPH和PCa患者在性激素受体表达上的差异无显著意义;PCa患者中AR表达阳性者平均生存时间长于AR阴性者,后者的预后较差,对AR阴性者行激素治疗效果不确定。
Objective： To investigate the relationship between the androgen receptor （ AR）, oestrogen receptor（ER） and progesterone receptor （PR） by assaying the distributions of these three receptors in the both beingn prostate hyperplasia（BPH） and prostatic cancer （PCa） tissues, then to explore the difference of the effects of hormonal treatment between the AR positive and AR negative in PCa pa- tients. Methods ： To observe AR, PR and ER expressions in 30 cases of BPH and 32 cases of PCa tissues by DAKO Envision methods. Results： There were 22 AR positive, 10 ER positive and 6 PR positive cases in 30 BPH patients, and there were 18 AR positive, 14 ER positive and 2 PR positive in 32 PCa patients. There was no significant difference between the two groups. The survival time was 6.41 and 4.28 years for the AR positive and AR negative respectively in 30 PCa patients. The AR positive patients lived longer than the AR negative （ P 〈 0.05 ）. Conclusion ： These three receptors cant result in PCa and the effects of hormonal treatment on AR negative PCa patients is not certain.
出处
《中华男科学杂志》
CAS
CSCD
2006年第1期50-52,56,共4页
National Journal of Andrology
关键词
前列腺癌
雄激素受体
雌激素受体
孕激素受体
良性前列腺增生
prostate cancer
androgen receptor
oestrogen receptor
progesterone receptor
beingn prostate hyperplasia
